Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: OTHER: Biomarker Analysis|DRUG: Enzalutamide|OTHER: Pharmacological Study|DRUG: Taselisib
Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: National Cancer Institute (NCI)|Translational Breast Cancer Research Consortium|Conquer Cancer Foundation|Genentech, Inc.